POTASSIUM PHOSPHATES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM PHOSPHATES (POTASSIUM PHOSPHATES).
Phosphate ion is essential for energy metabolism, buffer systems, and bone mineralization. Potassium is a critical intracellular cation for nerve conduction, muscle contraction, and acid-base balance. Coadministration restores electrolyte balance and provides phosphate for cellular function.
| Metabolism | Phosphate is primarily excreted by the kidneys. Potassium is also mainly eliminated renally. There is no hepatic metabolism of the salts. |
| Excretion | Renal: approximately 90% as phosphate (reabsorbed variably depending on dietary intake and parathyroid hormone activity). Fecal: <10%. |
| Half-life | Not applicable as a drug; endogenous phosphate has a terminal elimination half-life of 6-8 hours in the setting of renal impairment, but is not clinically significant in normal physiology. |
| Protein binding | Approximately 10-20% bound to albumin; remainder is free or complexed with cations. |
| Volume of Distribution | 0.15-0.25 L/kg; reflects distribution primarily in extracellular fluid and bone (major storage site). |
| Bioavailability | Oral: 60-70% (varies with renal function and vitamin D status). |
| Onset of Action | IV: Immediate (within minutes) for correction of hypophosphatemia. Oral: 2-4 hours for measurable serum phosphate increase. |
| Duration of Action | IV: 4-6 hours for therapeutic effect on serum phosphate levels. Oral: 6-8 hours for sustained increase. |
20-40 mEq elemental phosphorus intravenously over 4-6 hours, typically in adults; dose expressed in mmol phosphate: 10-15 mmol phosphate IV over 4 hours. Oral: 1-2 g (250-500 mg elemental phosphorus) 4 times daily.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m2) due to risk of hyperphosphatemia; adjust based on serum phosphate levels; reduce dose or increase interval in moderate impairment (eGFR 30-59 mL/min/1.73m2). |
| Liver impairment | No specific Child-Pugh based adjustments; caution in severe hepatic dysfunction due to potential electrolyte imbalances; monitor serum phosphate and calcium. |
| Pediatric use | IV: 0.5-1.5 mmol phosphate/kg over 4-6 hours (max 15 mmol/dose); oral: 2-3 mmol phosphate/kg/day divided q6h. Doses based on phosphorus needs. |
| Geriatric use | Start at lower end of dosing range due to age-related renal function decline; monitor renal function and serum phosphate closely; adjust intervals if creatinine clearance <50 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM PHOSPHATES (POTASSIUM PHOSPHATES).
| Breastfeeding | Safety unknown. No data on excretion into human milk. M/P ratio not established. Caution advised. Use only if benefits outweigh risks. |
| Teratogenic Risk | No teratogenic effects reported in human studies. Potassium phosphate is FDA Pregnancy Category C. Inadequate data in pregnant women. Animal studies not available. Use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hyperkalemia, hyperphosphatemia, hypocalcemia, severe renal impairment (oliguric or anuric), Addison's disease, acute dehydration, extensive tissue necrosis, severe burns, or conditions with high potassium or phosphate levels.
| Precautions | Use with caution in patients with renal impairment, cardiac disease, hyperkalemia, hyperphosphatemia, hypocalcemia, or dehydration. Monitor serum potassium, phosphate, calcium, and renal function regularly. Avoid rapid infusion due to risk of cardiac arrhythmias. |
Loading safety data…
| Monitor serum potassium, phosphorus, calcium, magnesium, and creatinine. Assess for signs of hyperphosphatemia, hypocalcemia, and hyperkalemia. ECG monitoring recommended with rapid infusion or high doses. |
| Fertility Effects | No data on effects on fertility in humans. Animal studies not available. |